Name: 5th Annual MarketsAndMarkets Next-Gen Immuno-Oncology Conference
Start: 2022-06-23
End: 2022-06-24
Location: Hyatt Regency Boston/Cambridge

WHAT TO EXPECT

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
New Antibody Formats & Adoptive Cell Therapy
Role of Biospecimen science in Clinical Immuno-Oncology Biomarkers: Lessons learned Lokesh Agrawal, Program Director Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NIH)	09:00 - 09:30
Methods for Epigenetic Analysis for Immunological and Oncological Related Therapies. Matthew Poulin, Scientific Director, EpigenDx	09:30 - 10:30
One Size Does Not Fit All: Tailor Made Precision Diagnostics from Sample to Insight Jennifer Elliott , Senior Director, Oncology & Precision Medicine , Qiagen	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
In vivo modeling of CD3 bispecific efficacy and toxicity Alison Crawford, Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.	11:15 - 11:45
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	11:45 - 12:15
Drugging the Undruggable: Nuclear-Specific Beta Catenin Small Molecule Degrader Sam Shrivastava, CEO, Founder, Asha Therapeutics	12:15 - 12:45
From Cold to Hot: Novel Therapeutic Modulation of the Tumor Microenvironment Bradlee Heckmann, CSO, Asha Therapeutics	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
Presentation by Angle Plc.	14:15 - 14:45
Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices	14:45 - 15:15
Immune Checkpoint inhibitors in Resectable Gastroesophageal Cancers-a Window of Opportunity Sarbajit Mukherjee , Assistant Professor, Oncology Roswell Park Comprehensive Cancer Center	15:15 - 15:45
Afternoon Refreshments and Poster Presentations \| One-to-One Networking Meetings	15:45 - 16:30
Panel Discussion: Future directions in cell therapy. Beyond CD19 CARs?	16:30 - 17:00
Creating therapies using the natural biology of T cells to treat patientswith solid tumors. Paul Lammers, President & CEO, Triumvira Immunologics	17:00 - 17:30
NK Cell targeted therapy in IO	17:30 - 18:00
End of Day 1 followed by Drinks, Reception and Networking
Closing remarks from the Chairman - End of Day 1	18:00 - 18:15

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
New Immune Checkpoints, Biomarker and Tumour Microenvironment
Keynote Presentation - SUPLEXA Therapeutic Cells : Individualized blood-derived adoptive cellular therapy to treat cancer! Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	09:00 - 09:30
Engineering a Rational Approach to Personalized Oncology Therapies Colin Brenan, CEO, Kibur Medical Inc.	09:30 - 10:00
Addressing Tumor Heterogeneity with non-viral Oncolytic agents - an unsolved issue in Cancer Immunotherapy Oystein Rekdal, CEO, Lytix Biopharma	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
New data on the usefulness of Immunoscore IC® as an immune biomarker in metastatic NSCLC and CRC Jerome Galon, Chief Scientific Officer of Immuno-Oncology , HalioDx, now part of Veracyte	11:15 - 11:45
Autonomous IL-36R Signaling Reprograms Neutrophils into Potent Anti-tumor Effectors Cells Rajkumar Noubade, Director, Gilead Sciences	11:45 - 12:15
ICI with Chemotherapy: why and how? Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron	12:15 - 12:45
Attivare Tx: An off-the-shelf solution that generates a personalized immune response Jessica McDonough, Co-Founder, Attivare Therapeutics	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
Soluble TNFα blockade sensitizes HER2-positive breast cancer to trastuzumab subverting immunosuppression Roxana Schillaci, Principal Researcher, Argentina National Council of Scientific Research	14:15 - 14:45
Individualized neoantigen directed immunotherapy requires Individualized translational biomarkers. Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	14:45 - 15:15
Closing remarks from the Chairman - End of Day 2 Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron	15:15 - 15:25